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Abstract
Background: All aged individuals with a chronic condition and those with 65 and more years are at increased risk
of severe influenza post-infection complications. There is limited research on cases averted by the yearly vaccination
programs in high-risk individuals. The objective was to estimate the impact of trivalent seasonal influenza
vaccination on averted hospitalizations and death among the high-risk population in Portugal.
Methods: The impact of trivalent seasonal influenza vaccination was estimated using vaccine coverage, vaccine
effectiveness and the number of influenza-related hospitalizations and deaths. The number of averted events (NAE),
prevented fraction (PF) and number needed to vaccinate (NVN) were estimated for seasons 2014/15 to 2016/17.
Results: The vaccination strategy averted on average approximately 1833 hospitalizations and 383 deaths per
season. Highest NAE was observed in the ≥65 years population (85% of hospitalizations and 95% deaths) and in the
2016/17 season (1957 hospitalizations and 439 deaths). On average, seasonal vaccination prevented 21% of
hospitalizations in the population aged 65 and more, and 18.5% in the population with chronic conditions. The
vaccination also prevented 29% and 19.5% of deaths in each group of the high-risk population. It would be needed
to vaccinate 3360 high-risk individuals, to prevent one hospitalization and 60,471 high-risk individuals to prevent
one death.
Conclusion: The yearly influenza vaccination campaigns had a sustained positive benefit for the high-risk
population, reducing hospitalizations and deaths. These results can support public health plans toward increased
vaccine coverage in high-risk groups.
Background
The annual circulation of influenza virus causes epi-
demics that can lead to a considerable burden of
hospitalization and death, especially for a sub-group of
the population with a high risk of influenza complica-
tions. It has been estimated that annually influenza is re-
sponsible for an excess of respiratory deaths that ranged
from 4.0 to 8.8 per 100,000 worldwide, and these figures
increased with age, causing an excess of 2.9 to 44.0 per
100 000 individuals in the 65 to 74 age group [1]. In
Portugal, influenza burden patterns are similar, and in
the all-age population, influenza epidemics have been es-
timated to be associated with an average of 24.7 all-
cause excess deaths per 100,000 [2] and 19.4 per 100,000
excess pneumonia and influenza hospitalizations [3].
Besides age, the presence of certain medical condi-
tions, namely diabetes, obesity, immunodeficiency and
chronic respiratory, cardiovascular, kidney and renal dis-
eases, are well-established risk factors for severe influ-
enza complications such as hospitalizations, intensive
care and death [4].
In Portugal, an at-risk based vaccination program has
been in place at least since 2001/2002. In accordance
with the National Directorate for Health clinical guide-
lines [5], influenza vaccination is strongly recommended
to those at higher risk for influenza complications
(chronic and immunocompromised patients older than
6months of age, pregnant women), as well as those aged
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65 and over and to institutionalized to whom the vaccine
is offered free of charge. Seasonal influenza vaccination
is also recommended to health professionals and other
caregivers.
Every year seasonal influenza vaccination campaigns
with inactivated trivalent vaccine start in early October
run throughout the fall and winter. Despite gradual in-
crease in influenza vaccine uptake in the 65 years and
older population [6], in Portugal, like in most other
European Union (EU), vaccination coverage (VC) still
has not reached the target of 75% set by the World
Health Organization and the European Commission
(EC) [7]. Individuals with chronic conditions have even
lower seasonal influenza vaccine coverage’s, that ranged
between 32.3% in 2015/16 and 41.0% in the 2017/18 sea-
son [8].
To increase the acceptability of the vaccine, it is im-
portant to quantify the benefits of annual influenza vac-
cination, namely by estimating its impact at the
population level. Influenza vaccine effectiveness (IVE)
studies are conducted in Europe every season and allow
early and end of season estimates on the reduction of
medically attended confirmed influenza infections, either
at primary care or hospital level [9–11]. However, popu-
lation data on influenza-associated outcomes prevented
each season by influenza vaccination, in high-risk popu-
lations, is scarce. Moreover, measuring the impact of the
influenza vaccination strategy every season is methodo-
logically challenging, as influenza vaccination pro-
grammes are in place for several decades, which inhibit
the before/after comparison of the introduction of this
public health intervention. To overcome this, some au-
thors use an ecologic approach that permits the estima-
tion of influenza vaccination impact using data on
vaccine coverage, vaccine effectiveness and the number
of observed influenza events [12–16].
This study aimed to estimate, the influenza-related
hospitalizations and intra-hospital deaths attributable to
influenza averted by seasonal influenza vaccination strat-
egy, during the influenza seasons 2014/15 to 2016/17, in
individuals 65 years and older and those, at any age, with
comorbidity that represents a high risk group for influ-
enza complications.
Methods
Hospitalization data
We developed an observational retrospective ecologic
study using the National Hospital Discharge Database.
This database covers all public hospitals in Portugal
mainland and includes demographic data, diagnosis, pro-
cedures, length of stay and discharge outcomes for all
episodes of hospital care. In the 2006–2016 period, this
database included approximately 79% of all hospital ad-
missions that occurred in Portugal [17]. Diagnoses and
some procedures (laboratory results not included) are
coded using the International Classification of Diseases
(ICD) - 9th Revision Clinical Modification (ICD-9-CM)
version [18] until 1st January 2016 and ICD-10-CM [19]
onwards. Final validated databases are available for re-
search after every 9 to 12months.
Study population
The target population of this study is high-risk individ-
uals, namely, aged 65 and older or < 65 years with a
chronic condition (diabetes, chronic respiratory, cardio-
vascular, kidney and renal diseases, obesity, immunodefi-
ciency) for which the influenza vaccine is recommended
[20–22]. An individual was considered as having a
chronic condition if it was hospitalized and had a sec-
ondary diagnosis within a set of chronic conditions pre-
sented in Table 1.
To estimate the number of high-risk individuals in
Portugal, we used the population estimates from the na-
tional statistical office (Statistics Portugal) [23] and the
proportion of self-reported chronic conditions in the 0–
4 and 15–64 age groups from two health surveys repre-
sentative at National and regional level [24, 25].
Severe influenza-related events
We considered two severe influenza-related outcomes:
hospitalizations (admissions for > 24 h) and intra-
hospital deaths attributable to influenza.
Hospitalizations
Hospital admissions due to influenza were obtained by
multiplying the weekly number of severe acute influenza
respiratory illness (SARI) hospitalizations by the weekly
proportion of SARI influenza positivity. The proportion
of influenza-positive was obtained from the hospital-
based Portuguese laboratory network for the diagnosis
of influenza [26].
A SARI hospitalization was defined as an episode with
hospital stay length higher than 24 h with a primary
diagnosis coded as any of SARI codes defined in Inte-
grated Monitoring of Vaccines Effects in Europe (I-
MOVE+) protocol [27] (Table 2).
Deaths
Intra-hospital deaths attributable to influenza (from this
point forward designated as deaths) were estimated
using the hospital discharge outcome information. The
number of deaths that occurred in patients hospitalized
with SARI diagnosis during the study period was multi-
plied by the proportion of influenza-positive, obtained
from the Portuguese laboratory network for the diagno-
sis of influenza [26].
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Study period
The impact of the influenza vaccine national program
was estimated for three seasons, 2014/15, 2015/2016 and
2016/17. For each season the analysis was restricted to
the epidemic periods. Epidemic periods were established
by the primary care-based Portuguese sentinel influenza
surveillance system (Table 3). For each season, the study
period comprises the epidemic periods, plus 3 weeks lag
as more severe outcomes are expected to occur with
delay.
Number of averted severe influenza-related events
prevented fraction
To assess the annual impact of the influenza vaccination
programmes we estimated the number of severe
influenza-related events (IRE) among the high-risk
population averted by vaccination (NAE), the respective
disease prevented fraction (PF) and the number of high-
risk individuals in the population needed to be vacci-
nated to avoid one IRE (NNV).
NAE measures the impact of the vaccination program
in absolute terms and represents the difference between
observed IRE (n) and IRE expected in the absence of the
vaccination program (N) and was estimated as:
NAE ¼ N− n ¼ n ∙ IVE ∙VC
1− VC ∙ IVEð Þ
where n – observed IRE, IVE – Influenza vaccine effect-
iveness, VC – vaccine coverage (details on the formula
available at Additional file 1).
The PF, estimated as PF = NAE/(n + NAE), measures
the impact of vaccination in relative terms and repre-
sents the proportion of averted IRE out of the number
of IRE in the population without influenza vaccination
program [12–14, 16, 28].
The number needed to vaccinate was also computed
as:
NNV = 1/(IVE·N/Population).
Vaccine coverage (VC)
The influenza vaccination coverage was estimated using
the influenza vaccine coverage monitoring system [6,
29], a population-based survey of a sample of approxi-
mately 1000 households from Portugal mainland, se-
lected using random digit dialling of mobile and landline
phones. In each household, one individual aged 18 or
more is interviewed providing information on his/her
vaccination status and the vaccination status of the other
household elements. The questionnaire also includes in-
formation on chronic conditions. Vaccine coverage was
estimated for the population with conditions for which
the vaccine is recommended and for the population aged
65 and more years.
Influenza vaccine effectiveness (IVE)
We used hospital-based meta-analysis type/subtype IVE
estimates. IVE among those aged 65 and older and with
less than 65 years [30] were weighted by the distribution
of circulating influenza type/subtypes virus in each sea-
son in Portugal. Reported match/unmatched vaccine in-
formation [30] was considered. Data on circulating
influenza type/subtypes detected in the hospital settings
were obtained from the Portuguese Hospital laboratory
network for the influenza diagnosis [26, 31].
Vaccine effectiveness against intra-hospital deaths of
56% [14 to 77%] reported by Casado et al. [32] for the
Spanish population was used for all high-risk groups.
Table 1 List of International Classification of Diseases (ICD) 9th and 10th version codes for chronic conditions
ICD 9th version ICD 10th version
Respiratory 011, 490–511, 512.8, 513–517, 518.3, A15, J40–47, J60–94, J96, J99, J182,
518.8, 519.9, 714.81 M34.81, M05.10
Cardiovascular 746.9 Q24.9
402.0–402.91 I11.0-I11.9
428.42, 428.32, 482.22 I50.22, I50.32, I50.42
412,0-412,9, 413.0–413.9, 414.0–414.9 I25.2, I20.8, I20.1, I20.9, I25.0-I25.9
Renal 581.0–581-9, 585.0–585.9 N18, N04
Kidney 571.0–571.9 K70, K74, K72.1
576.2
Hematologic 282.4, 282.5, 282.6 D56, D57
Imunocompromised 042, 279, V08, V42 B20, D80–84, D89.8–9, Z21, Z94
Diabetes mellitus 250 E10–11; Z94.0-Z94.4, Z94.6-Z94.9
Genetic conditions 273.4 E88.01
Obesity 278.00, 278.01, 278.03 E66.01, E66.2, E66.9
ICD International Classification of Diseases (ICD)
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Uncertainty
To estimate 95% confidence intervals for NAE, NNV, and
PF we used Monte Carlo simulations (see more detail
in Additional file2). We assumed a Poisson distribution for
the number of influenza-related events and Normal distri-
butions for log (1-IVE) and log (VC/(1-VC)) [13]. The
Table 2 List of diagnosis codes for which patients could be screened for onset of SARI symptom, IMOVE+ hospital based IVE studies
Category Morbidity ICD-9 ICD-10
Influenza like illness Cough 786.2 R05
Difficulty breathing 786.05 R06
Sore throat 784.1 R07.0
Dysphagia 787.20 R13
Fever 780.6 R50.9
Headache 784.0 R51
Myalgia 729.1 M79.1
Fatigue/malaise 780.79 R53.1, R53.81, R53.83
Cardiovascular diagnosis Acute myocardial infarction or acute coronary
syndrome
410–411, 413–
414
I20–23, I24–25
Heart failure 428 to 429.0 I50, I51
Respiratory diagnosis Emphysema 492 J43.9
Chronic obstructive pulmonary disease 496 J44.9
Asthma 493 J45
Myalgia 729.1 M79.1
Dyspnoea/respiratory abnormality 786.0 R06.0
Respiratory abnormality 786.00 R06.9
Shortness of breath 786.05 R06.02
Other respiratory abnormalities 786.09 R06.00, R06.09, R06.3,
R06.89
Infections Pneumonia and influenza 480–488.1 J09-J18
Other acute lower respiratory infections 466, 519.8 J20-J22
Viral infection, unspecified 790.8 B34.9
Bacterial infection, unspecified 041.9 A49.9
Bronchitis 490, 491 J40, 41
Inflammation SIRS non infectious without acute organ dysfunction 995.93 R65.10
SIRS non infectious with acute organ dysfunction 995.94 R65.11
Diagnoses related to deterioration of general
condition or functional status
General physical deterioration, lethargy, tiredness 780.79 R53.1, R53.81, R53.83
Anorexia 783.0 R63.0
Feeding difficulties 783.3 R63.3
Abnormal weight loss 783.21 R63.4
Other symptoms and signs concerning food and fluid
intake
783.9 R63.8
Desorientation/Altered mental status 780.97 R41.0
Dizziness and giddiness 780.4 R42
Infective delirium 293.0, 293.1 F05
Coma 780.01 R40.2
Transient alteration of awareness 780.02 R40.4
Other alteration of consciousness (Somnolence, stupor) 780.09 R40.0, R40.1
Febrile convulsions (simple), unspecified 780.31 R56.00
Complex febrile convulsions 780.32 R56.01
aSIRS Systemic inflammatory response syndrome
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distributions parameters were derived from respective point
estimates and 95% confidence intervals. We drew 10,000
simulations samples of influenza-related events, IVE and
VC to obtain empirical distributions of NAE, NNV, and PF
in each season and average across three seasons. We used
the 2.5 and 97.5 percentiles of these empirical distributions
as lower and upper limits of the 95% confidence intervals.
Results
We estimate that during the study period there were
about 3.82 million high-risk individuals in Portugal tar-
geted by the National vaccination program: 2.07million
were aged 65 and more and about 1.75 million aged less
than 65 years and had a chronic condition for which the
influenza vaccine is recommended.
During the study period, the estimated number of
SARI hospitalizations among high-risk individuals
ranged from 21,955 (season 2016/17) to 29,099 (season
2014/15) (Table 3). Influenza deaths varied between 778
in season 2015/16 and 1134 in season 2014/15.
The most frequent comorbidities of hospitalized SARI
patients were chronic respiratory diseases (46%),
followed by diabetes (32%) and cardiovascular diseases
(24%). The highest number of influenza-related hospital-
izations and deaths was estimated in season 2014/15, a
B/Yamagata dominant season but with A(H3N2) circula-
tion (7946 hospitalizations and 1134 deaths). Influenza
vaccine effectiveness was lower in the 2014/15 season
than in the other seasons. Overall, point estimate IVE
was lower in the individuals aged 65 and more years
than in younger individuals with chronic conditions. In
contrast, vaccine coverage was higher in the older popu-
lation, increasing from 49.8% in the 2014/15 season to
57.5% in the 2016/17 season.
On average, per season, the influenza vaccination cam-
paign averted approximately 1833 hospitalizations and
383 deaths in the Portuguese high-risk population
(Table 4). The highest number of averted events oc-
curred in the population aged 65 and more years and
the 2016/17 season, a season with a predominance of
A(H3N2) virus.
Overall, the vaccination strategy prevented on aver-
age, 21 and 18.5% of influenza hospitalizations in
those 65 years and older and under 65 years with
chronic conditions, respectively, and 19.5% and 37.4%
of deaths in the < 65 years and in the older adult
population, respectively. To prevent one influenza-
related hospitalization or death, we would need to
vaccinate on average 3360 and 60471 high-risk indi-
viduals, respectively.
Table 3 Distribution per season of the number of severe acute respiratory infections (SARI) hospitalizations and deaths, SARI
Influenza-related hospitalizations and deaths, influenza vaccine effectiveness and vaccine coverage estimates for ≥65 years and < 65
years with a chronic condition
Season features 2014/15 2015/16 2016/17
Epidemic period w1 to w7/2015 w53/2015 to w7/2016 w48/2016 to w1/2017
Dominant type/subtype B/Yam AH1N1pdm09 AH3
SARI Hospitalizations
≥ 65 years (n) 24,720 21,913 18,724
Chronic condition (n) 4379 4595 3231
SARI deaths
≥ 65 years (n) 3824 3044 2942
< 65 years with a chronic condition (n) 198 196 137
Influenza hospitalizations
≥ 65 years 6742 5107 6003
< 65 years with a chronic condition 1204 1069 1031
Influenza deaths
≥ 65 years 1078 731 909
< 65 years with a chronic condition 56 47 42
Influenza vaccine effectiveness (IVE %)
≥ 65 years[95%CI] 29.0 [14.7 to 43.4] 49.1 [26.4 to 71.7] 42.9 [33.0 to 52.8]
< 65 years [95%CI] 46.1 [20.9 to 71.3] 53.0 [34.9 to 71.1] 58.9 [38.1 to 79.6]
Vaccine coverage (VC %)
≥ 65 years[95%CI] 49.8 [41.3 to 58.4] 50.1 [42.1 to 58.1] 57.5 [50.8 to 64.1)
Chronic condition [95%CI] 34.2 [28.1 to 40.9] 32.3 [26.8 to 38.4] 39.7 [33.7 to 45.9]
SARI severe acute respiratory infections, w week, IVE influenza vaccine effectiveness, CI confidence intervals, VC vaccine coverage
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Discussion
We estimated that during the influenza seasons 2014/15,
2015/16 and 2016/17, the trivalent inactivated seasonal
influenza vaccination strategy averted each season, on
average, more than 1830 hospitalizations and 380 deaths
in the high-risk population in Portugal.
Overall, the impact of the program was higher in the
population aged 65 and more years, a sub-group with higher
VC but systematically lower IVE, in which it accounted for
86 and 95% of the total number of averted hospitalizations
and deaths. These results reflect not only the higher risk of
complication of that population but also the potential gain
that could be achieved by increasing the vaccine coverage.
In seasons with lower influenza vaccine, performance high
vaccine coverage could balance and allow reasonable pre-
vented fraction. Also, it demonstrate that, even with limited
effectiveness, the influenza vaccination program prevented a
considerable number of hospitalizations and deaths associ-
ated with influenza in the 65 years and older population.
The results also show that, even in seasons with a mis-
match, between circulating virus and vaccine composition,
like the 2014/15 season, vaccinating this high-risk group of
individuals averted 1346 hospitalizations and 264 deaths.
This included averting 5% premature deaths of individuals
aged < 65 years. The highest number of averted events oc-
curred in the A(H3N2) dominant 2016/17 season, where
approximately 2268 hospitalizations and 442 deaths were
prevented. These results are important given that in seasons
with A(H3N2) predominant circulation i) a considerable
burden of influenza is observed in the target vaccination
subgroup and ii) vaccine effectiveness tends to be low
against this virus sub-type [30, 33]. Besides, in seasons with
A(H3N2) predominance, the influenza vaccination impact
is limited in preventing primary care consultations by influ-
enza [34] and thus this result reinforces the main objective
of the influenza vaccination strategy as the reduction of se-
vere complications by influenza.
The estimated prevented fractions indicate that on aver-
age, per season, the influenza vaccination strategy prevented
21% of the hospitalization in the population aged 65 and
more and 18.5% in the < 65 years with a chronic condition.
Season specific estimates in 2015/16 season (PF = 24.3%)
was comparable to estimates obtained in a study for the
USA population for the same season (22.5, 95% CI: 13.5–
31.4) [35] and were also comparable to estimates reported
for the USA population in other seasons with predominant
circulation of A(H1)pdm09 virus [36]. However, for the
2014/15 and 2016/17 season, our estimates were higher than
the reported for the USA. For instance, it was double than
the 7% estimates published for the 2014/15 season [15, 37]
and 11.5% estimates for the 2016/17 season [38]. Consider-
ing that the PF mainly depends on the VC and IVE
Table 4 Estimates of the annual average and seasonal prevented fraction and number of averted influenza hospitalizations and
deaths attributed to the vaccine program, for seasons 2014/15 to 2016/17
IRE Season Average
2014/15 2015/16 2016/17
Hospitalization
≥ 65 years
NAE (n) [95%CI] 1124 [443–1863] 1644 [460–2799] 1957 [1326–2657] 1584 [1058–2097]
PF (%)[95%CI] 14.3 [6.2–21.6] 24.3 [8.2–35.4] 24.6 [18.1–30.7] 21.0 [15.1–26.1]
NNV (n)[95%CI] 890 [565–2233] 621 [384–2050] 616 [473–882] 741 [553–1426]
< 65 years with chronic condition
NAE (n) [95%CI] 222 [42–383] 218 [106–326] 311 [135–473] 249 [158–337]
PF (%)[95%CI] 15.6 [3.3–24.1] 16.9 [9.1–23.4] 23.2 [11.6–31.5] 18.5 [12.5–23.4]
NNV (n) [95%CI] 2657 [1628–10,924] 2564 [1857–5172] 2200 [1540–4957] 2619 [1921–6015]
Deaths
≥ 65 years
NAE (n) [95%CI] 409 [81-721] 281 [52-489] 427 [95-743] 371 [198-541]
PF (%) [95%CI] 27.7 [7.0-40.1] 27.5 [6.7-40.1] 31.9 [9.4-45.0] 29.0 [18.0-37.4]
NNV (n) [95%CI] 2416 [1459-10,267] 3613 [2166-15,078] 2796 [1633-10,422] 3241 [1845-10,141]
< 65 years with chronic condition
NAE (n) [95%CI] 13 [3–22] 10 [2–49] 12 [3–20] 12 [6–16]
PF (%)[95%CI] 18.9 [4.8–27.9] 17.9 [4.3–26.1] 22.0 [6.5–31.7] 19.5 [11.8–25.4]
NNV (n)[95%CI] 45,211 [29,413–176,520] 54,149 [35,348–205,119] 58,216 [37,146–206,237] 57,230 [37,610–176,457]
IRE influenza related event, NAE number of averted events, CI confidence interval, PF prevented fraction, NNV number needed to vaccinate
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estimates [39] and that VC was comparable between coun-
tries and was stable along the period in study, the main con-
tributor to the observed differences was most probably IVE.
In our study, we used type/subtype specific meta-analysis
estimates and weighed to account for the virus in circula-
tion. In the 2014/15 season, although the mismatched
A(H3N2) virus circulated in Portugal, the predominant
virus was type B virus [40]. As such, season-specific IVE
for 2014/15 season was estimated to be 29% in the more
than 65 years population and 46% in the ones with chronic
conditions, thus justifying the increased estimated PF. In
the 2016/17 season, the predominant A(H3N2) in
Portugal matched the vaccine strain and this study final
IVE estimates for the population aged 65 and more were
considerably higher than the 17% published in Europe
[41] and 20% in the USA [38].
Concerning the most severe outcome, we estimate that
19.5% or 29% of hospitalized influenza deaths were pre-
vented by the vaccination strategy. The comparison with
other studies is limited as most studies focus on older
adults and all-cause mortality [16] or cause-specific mor-
tality outcomes [13, 15]. Nevertheless, and though using
a conservative estimate of 56% reduction of influenza-
related intra-hospital deaths, we estimate that the vac-
cination strategy would prevent premature deaths in <
65 years population with chronic conditions.
To prevent one hospitalization or death we would need
to vaccinate additionally 3982 individuals aged 65 and more
years and 59,849 individuals with chronic conditions. These
results indicate that there is a potential increased benefit if
the 75% VC target would be achieved.
The results presented should be interpreted in light of the
study’s limitations. The ecologic nature of the study and the
use of several data sources limits the study external validity.
In relation to the study design, the main objective of the
study is to measure the impact of the influenza vaccination
programme and this is methodologically challenging. For
some infectious diseases, as pneumococcal pneumonia, the
impact of vaccination in the older adult Portuguese popula-
tion was measured by comparing hospitalizations rate be-
fore and after the introduction of the pneumococcal
conjugated vaccines [42]. However, for influenza vaccin-
ation, with a vaccination programme in place for long time,
such approach is not feasible. The method that we used to
estimate the influenza vaccination strategy impact has been
used by several countries [12–16, 28] and consists in evalu-
ating how the vaccination programme works at population
level, using as reference an hypothetical totally susceptible
population that has never been exposed to the intervention.
The methods measure only the direct effect of vaccin-
ation in the population and thus represents a more con-
servative estimate of the impact as does not account for
indirect effects. Also, there are some limitations to the
data. First, hospitalization and deaths were retrieved
from a hospital discharge database collected for adminis-
trative and hospital financing purposes, which covers ap-
proximately 79% of the national hospitalizations [17].
Another limitation of this database to estimate the im-
pact in each season is the time to have available data.
The hospitals are in the process of changing from ICD9
to ICD10 and this has delayed obtaining the final data-
base jeopardizing the use of annual estimation of vaccin-
ation strategy impact to prepare the next season. Finally,
this database includes diagnoses and some procedures
codes, however, laboratory results are not systematically
done nor available which prohibit the use of influenza
laboratory diagnoses directly from it. This limitation had
as consequence the need of using an external database
(from the hospital-based Portuguese laboratory network
for the diagnosis of influenza) to obtain an estimate of
the influenza hospitalized cases.
In our study, the VC was obtained from self-reported
data and restricted to non-institutionalized Portuguese
mainland residents. Given that VC is higher in the institu-
tionalized population, our VC results may be underesti-
mated and thus underestimation of impact results. Finally,
IVE against mortality may not represent the Portuguese
population, since we used VE derived from a study in a
population from Spain that could have a different distribu-
tion of chronic conditions and access to health care. Also,
the same estimate was used for all seasons and sub-group
of population and IVE is expected to vary between seasons
and in younger individuals.
The study has also considerable strengths. First, to our
knowledge, this is the first attempt to measure the vac-
cination impact in a population < 65 years with chronic
conditions. Considering that this subgroup is targeted by
influenza vaccination programs and is an important frac-
tion of the population (26.2% of population aged 15–64
years) our results demonstrate important benefits by the
seasonal vaccination in this sub-group. In a country with
low seasonal adherence to influenza vaccine uptake in
the group of the population with a chronic condition for
which seasonal influenza vaccination is recommended
[43], this information could be important to increase
vaccine coverage in this target group. Second, we used
an alternative method to estimate influenza severe bur-
den in Portugal to better fit the impact study. Given the
ecologic nature of the adopted approach, it was import-
ant to have specific outcomes and also that had corres-
pondence to the outcome of IVE estimates.
Previous research in Portugal provided estimates of in-
fluenza excess associated hospitalizations [3] and all-cause
deaths [2] that were based on time series approaches. Al-
though these methods are more comprehensive ap-
proaches and often used to measure influenza burden
[44], in our case, it was important to use specific
influenza-related outcomes for impact estimation. We
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used hospitalized SARI and intra-hospital deaths, re-
stricted to epidemic periods, to improve specificity. Also,
it was important to have an outcome that was highly cor-
related with IVE estimates. Finally, to increase external
validity we used i) a national discharge database, ii) an in-
fluenza laboratory diagnoses database that collects influ-
enza positivity results from hospitals distributed at
national level; iii) influenza vaccine effectiveness from
meta-analysis and iv) vaccine coverage estimates from a
population-based survey. Moreover, to reduce potential
heterogeneity related to different codification procedures,
the study was restricted to only 3 seasons, but that with
different pattern of the influenza virus circulation. All
these using registry/ monitoring data easily accessible that
can be replicable each season. Following the example of
the USA [45], these results, along with the burden and ef-
fectiveness results can be reported, so to better communi-
cate the influenza vaccination benefits.
Conclusion
The influenza vaccination strategy in place in Portugal
for the 65 and more years individuals and individuals
with chronic conditions, prevented on average 1833 hos-
pitalizations and 383 deaths per season. The applied
method identified and quantified the overall benefits of
the influenza vaccination program, even in seasons with
limited vaccine effectiveness. Also, it captured the im-
pact of several outcomes with different levels of severity.
Given the already mentioned, multiple data source
ecological nature of the study; further investigations are
warranted, with the perspective of evaluating the sens-
ibility of the approach in other seasons, countries and
data sources.
The knowledge on health benefits in terms of influenza-
related hospitalizations and deaths averted by the vaccin-
ation program will allow better understanding the impact
of the national vaccination strategies and strengthening
public health communication with the general public and
policymakers, to support public health plans towards the
increase of vaccine coverage in high-risk groups.
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